Physician profile
Christopher J Guzik
NPI 1396762126
$1,960.54
in general payments reported to CMS, 2019-2025
28 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.80 · 2022: $248 · 2023: $367 · 2024: $650 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $263.90 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $255.88 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $189.59 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $156.87 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Antares Pharma, INC. | $96.83 | 2019-2024 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $88.91 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $88.76 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $79.32 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $75.26 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $57.29 | 2022-2025 | Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.02 | 2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.31 | 2022-2025 | Jardiance |
| Asd Specialty Healthcare, LLC | $49.80 | 2019 | |
| Esperion Therapeutics, INC. | $47.53 | 2023-2025 | Nexletol |
| Sanofi Pasteur INC. | $46.15 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $42.44 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $41.80 | 2024-2025 | |
| Abbvie INC. | $40.90 | 2023-2024 | |
| Inspire Medical Systems, INC. | $39.39 | 2024-2025 | Inspire |
| Astellas Pharma US INC | $38.54 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $34.68 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $21.15 | 2024 | |
| Indivior INC. | $20.06 | 2023 | Sublocade |
| Corcept Therapeutics | $19.12 | 2025 | Korlym |
| Phadia US INC. | $18.96 | 2023 | Immunocap |
| Tolmar, INC. | $15.68 | 2023 | |
| Shield Therapeutics INC | $14.70 | 2025 | |
| Lucid Diagnostics INC. | $13.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Guzik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.